The medication is used across two main therapeutic areas.

Supporting Patients with Advanced Systemic Conditions

This therapy is commonly used to help with certain conditions presenting with systemic or localized discomfort, which is relevant for use when the PIK3CA mutation is confirmed and the cancer has progressed following prior hormone treatment. The use of this medicine is typically applied in scenarios where additional management of discomfort is required in situations where concurrent use with an anti-estrogen is appropriate. It is relevant for easing the symptomatic burden associated with these conditions characterized by periods of heightened symptoms, and may assist with maintaining functional stability.

“The therapy may assist with maintaining overall stability during challenging symptomatic periods.”

Addressing Symptoms Related to Overgrowth and Functional Strain

Piqray is applied in addressing conditions involving episodic or fluctuating manifestations that cause tissue overgrowth, known as PIK3CA-Related Overgrowth Spectrum (PROS). It is relevant for use in both adults and pediatric patients requiring systemic therapy and is applied in clinical settings that involve acute or unstable symptom patterns associated with severe overgrowth. This treatment provides support that helps ease the overall symptom burden associated with the excessive growth, such as symptoms related to physical discomfort. It contributes to improved day-to-day comfort and may assist with managing the symptoms that create noticeable functional strain in affected body areas.

Key Therapeutic Contexts: The medicine is used for advanced breast cancer and the PIK3CA-Related Overgrowth Spectrum (PROS), conditions defined by specific PIK3CA mutations.

Piqray (alpelisib) is generally indicated for postmenopausal women and men with HR-positive, HER2-negative, advanced breast cancer that harbors a PIK3CA mutation. Eligibility is strictly determined by regulatory criteria, defining groups who must not use the medicine and special populations requiring specific caution.

Contraindications (Must Not Use)

Piqray is contraindicated in patients with a history of severe hypersensitivity to alpelisib or its components. It is also permanently discontinued if Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS), Erythema Multiforme (EM), or Toxic Epidermal Necrolysis (TEN), are confirmed.

Eligibility Restrictions

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Piqray (Alpelisib) primarily through its involvement as a substrate for specific metabolic enzymes and drug transporters. The drug's exposure, which is critical for its activity, can be significantly altered by co-administered substances.

Strong CYP3A4 inducers, such as rifampin and St. John's wort, must be avoided because they are documented to cause a substantial decrease in Alpelisib's plasma concentration, potentially reducing its efficacy. Conversely, coadministration with BCRP inhibitors must also be avoided, as they are officially documented to increase Piqray exposure, thereby raising the risk of adverse reactions. If avoiding BCRP inhibitors is not possible, close patient monitoring is required.

In addition to drug-drug interactions, a crucial requirement is the interaction with food: Alpelisib must be taken immediately following food. This is a mandatory administration condition based on official findings that food intake significantly enhances the drug's absorption. Furthermore, Alpelisib’s metabolic effect on blood sugar often necessitates the co-management of severe hyperglycemia with antidiabetic medications.

Selective Blockade of the PI3Kalpha Enzyme

The mechanism of alpelisib is defined by highly specific molecular targeting that disrupts an essential intracellular signaling network, resulting in the suppression of cellular growth signals. The primary mechanistic domain involves the targeted inhibition of the Phosphatidylinositol 3-Kinase alpha ( PI3Kalpha) enzyme. Alpelisib acts as a selective inhibitor, binding directly to the p110alpha catalytic subunit, preventing the enzyme from initiating its phosphorylation step. This action functionally reduces the dysregulated signaling patterns associated with the hyperactive enzyme.

Disruption of the AKT/ mTOR Signaling Cascade

By halting the initial PI3Kalpha step, alpelisib interrupts the entire PI3K/ AKT/ mTOR signaling cascade, a key pathway for regulating cell growth and replication. This suppression leads to the functional physiological effect of G0/G1 phase cell cycle arrest.

Synergy and Mechanism Limitations

The drug’s mechanism operates synergistically with an Estrogen Receptor (ER) degrader, a strategy addressing biological pathway crosstalk and potential compensatory signaling. However, the selective mechanism is constrained by the cell's ability to engage alternative Receptor Tyrosine Kinases (RTKs) or other PI3K isoforms (like PI3Kbeta in the context of PTEN loss), which results in the partial functional restoration of the proliferation signal.

Piqray (alpelisib) is administered by the oral route using film-coated tablets in available strengths of 50 mg, 150 mg, and 200 mg. The medicine is designed for continuous, once-daily use and must be taken at approximately the same time each day.

Official Dosing and Administration

The standard starting dose for advanced breast cancer is 300 mg once daily, typically achieved by taking two 150 mg tablets. Piqray is generally used as part of a combination regimen with fulvestrant. A separate starting dose of 250 mg once daily is recommended for use in adults being treated for PIK3CA-Related Overgrowth Spectrum (PROS).

No initial dose adjustment is required for older adults (65 years or older) or for mild-to-moderate renal impairment. For patients with severe hepatic impairment, a reduced starting dose is required.

Research evidence / Overview of studies for Piqray

This section provides an overview of the types of research studies that have been conducted for Piqray, describing what the studies examined and what patterns were reported, without making claims about effectiveness or giving clinical advice.

## Evidence for Advanced Hormone Receptor-Positive Breast Cancer

The primary body of evidence for the use of this drug in advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA gene mutation was derived from a large, randomized, double-blind, placebo-controlled trial. This study was designed to rigorously compare the effects of the combination therapy against a placebo combination in men and postmenopausal women whose cancer had already progressed after prior endocrine treatment.

Research examined the primary outcome of Progression-Free Survival (PFS), which monitored the time during which the disease was observed not to progress. Research also monitored the secondary outcome of Overall Survival (OS) and the Radiological Response Rate, which is the measured percentage of patients with tumor size reduction.

Research examined the patterns observed in Progression-Free Survival. Studies monitored the patterns related to the Radiological Response Rate. The final analysis of Overall Survival was not statistically significant in the measured outcome for the full patient population.

## Evidence for PIK3CA-Related Overgrowth Spectrum (PROS)

Research for this drug in the setting of the PIK3CA-Related Overgrowth Spectrum (PROS) focused on adults and children age two and older with severe manifestations of the condition. PROS is a condition marked by functional limitations and conditions where symptoms may vary in intensity.

The evidence base for this indication was derived mainly from a single-arm clinical study that used patient data collected retrospectively from an Expanded Access Program. The primary outcome monitored was the Radiological Response Rate, which is a measured reduction in the volume of the enlarged tissues or lesions at a specific time point. Secondary research explored patient-reported outcomes describing perceived discomfort and how these outcomes evolved over the defined study intervals.

Studies reported that the measured volumetric reduction was reported in a percentage of the PROS patient population. Data are still emerging, and research is ongoing in this area.

## Evidence in Special Patient Populations

Research explored whether data show patterns related to outcomes in specific patient subgroups. In the advanced breast cancer setting, the main trial included an examination of patients presenting with aggressive disease features, such as visceral metastases (cancer spread to organs like the liver or lungs). Research explored the relationship between this subgroup and Overall Survival measurements, noting patterns that were not reflected in the full study population.

For the PROS indication, the research included this broad range of ages presenting with the condition, as pediatric patients (age two and older) were evaluated in addition to adults in the single-arm study.

## Long-Term Studies and Durability of Response

Studies monitored responses over defined time intervals to understand the durability of the observed patterns. For the breast cancer indication, the follow-up for the main study extended over an intermediate-term period of over 30 months for some patients.

While these studies contribute to understanding symptom patterns and provide context regarding how outcomes evolved in the observed populations, long-term effects are not fully established. There is limited information for outcomes that extend many years beyond the observation period of the primary clinical trials.

## Research Gaps and Remaining Uncertainties

The evidence base, while extensive in certain areas, has several limitations that help contextualize what is known and what is still uncertain.

For the advanced breast cancer indication, the final research conclusion on Overall Survival was not statistically significant in the measured outcome for the full patient population. Additionally, some important findings about subsequent treatment sequences were evaluated in smaller, non-comparative study designs, meaning that comparative evidence is lacking in those areas.

For the PROS indication, the initial evidence relied heavily on a single-arm study that used retrospective data, which carries a lower evidence quality compared to a randomized trial. As this single-arm study utilized a surrogate measure (volumetric reduction) as its primary assessment, certainty remains low regarding definitive long-term functional improvement, and the initial approval was conditional, indicating that further confirmatory research is required. The results apply only to the specific populations studied, and data for certain groups remain insufficient.

Key Studies & References Clinical Review - Alpelisib (Piqray) - NCBI (Review assessing non-comparative evidence, including the BYLieve study)

Common questions about Piqray (FAQ)

Q: What is the maximum amount of time a patient typically stays on Piqray treatment?

A: According to the official product information, the duration of Piqray treatment is determined by the healthcare provider. Treatment is generally continued for as long as clinical benefit is observed, or until unacceptable side effects occur. Regulatory documents state that treatment is generally continued until the disease progresses or until unacceptable side effects occur.

Q: Is it common to need to start a diabetes medicine, like Metformin, while taking Piqray?

A: Studies and official information indicate that patients with pre-existing risk factors for high blood sugar may require intensified management. Healthcare providers may choose to start patients on an antidiabetic medicine before or at the beginning of Piqray treatment as a way to help manage or prevent severe high blood sugar.

Q: Can Piqray cause chronic fatigue or a significant drop in energy levels?

A: Official adverse reaction reports state that fatigue and asthenia (physical weakness or lack of energy) are both documented as very common side effects. These are frequently reported concerns among patients.

Q: Are changes in appetite and weight loss common side effects of Piqray?

A: Regulatory documents list decreased appetite and weight loss as common adverse reactions that patients may experience while taking Piqray. These effects often occur alongside other common gastrointestinal issues like diarrhea and mouth sores.

Q: Are there any specific foods, like grapefruit, that should be completely avoided with Piqray?

A: Official administration rules strictly require that Piqray be taken immediately following food to ensure proper absorption. Patients are advised to discuss all specific dietary concerns with a healthcare professional.

Q: Does Piqray affect vision, causing blurriness or eye pain?

A: Official documents report that blurred vision is a common adverse reaction for patients taking Piqray. Eye pain is not specifically documented in the list of common or very common side effects.

Q: How does Piqray interact with common pain relievers or fever reducers?

A: Piqray has the potential to decrease the effectiveness of other medicines that are processed by the CYP2C9 enzyme, which includes some common over-the-counter pain relievers. The product information states that close monitoring is required when co-administering Piqray with drugs processed by this enzyme.

Q: If I am a pre-diabetic, will Piqray automatically make my condition worse?

A: Regulatory information indicates that patients with pre-existing risk factors like pre-diabetes have a higher chance of developing severe high blood sugar ( hyperglycemia) while on Piqray. Regulatory information indicates that blood glucose levels should be optimized before starting treatment, and close monitoring by a healthcare provider is required.

Q: What should I do if I vomit shortly after taking my daily Piqray dose?

A: Dosing instructions state that if vomiting occurs after taking a dose, an additional dose should not be taken that day. The regular schedule should be resumed the following day at the regular time.

Q: Can Piqray affect my hair, like causing thinning or hair loss?

A: Yes, hair loss (alopecia) is listed as a common adverse reaction for patients receiving Piqray, according to official regulatory reports. This effect is monitored as part of the overall safety profile.

Q: Is it common for Piqray to cause dryness in multiple areas, such as the mouth and skin?

A: Inflammation or sores in the mouth ( stomatitis) are very common side effects which may involve dryness in the mouth and throat area. General forms of dryness, such as dry skin, are not documented among the most frequently reported adverse reactions.

Q: Can Piqray affect my sleep, causing insomnia or unusual sleepiness?

A: Official adverse event reports document that insomnia (difficulty sleeping) is listed as a common side effect of Piqray. Changes in sleep patterns should be discussed with a healthcare provider.

Q: Does Piqray affect fertility, and should male patients use caution?

A: Nonclinical studies in male animals showed adverse effects on reproductive organs. Due to the potential risk of harm to an unborn baby, the product information states that male patients with partners of reproductive potential are required to use effective contraception during treatment and for a period afterward.

Q: Can taking Piqray cause or worsen existing heart conditions, such as hypertension?

A: Studies and regulatory reports indicate that hypertension (high blood pressure) is a very common adverse reaction associated with Piqray treatment. The regulatory documents require that blood pressure be monitored regularly throughout therapy.

Q: Why is it important to monitor potassium and other electrolyte levels while on Piqray?

A: Regulatory information advises that due to the risk of severe diarrhea or colitis, electrolyte levels may be a concern. These issues are managed by monitoring and potentially replacing electrolytes, such as potassium, to prevent imbalance caused by gastrointestinal side effects.

Q: What kind of physical activity is generally recommended for managing fatigue while on Piqray?

A: While specific physical activity recommendations for fatigue are not detailed in the core label, general lifestyle measures, including physical activity, are recommended as part of managing the metabolic profile.

Q: Are there any special instructions for storing Piqray tablets?

A: Official storage instructions require that Piqray tablets be stored at controlled room temperature, kept in the original bottle, and kept tightly closed. The desiccant packet included in the container must not be removed, as it protects the medicine from moisture.

Q: Is it common to have dose interruptions or temporary stops in Piqray due to side effects?

A: Yes, regulatory guidelines confirm that dose interruption, reduction, or discontinuation may be necessary based on the severity of adverse reactions like high blood sugar, rash, or diarrhea. This is an established practice for managing side effects.

Q: What are the symptoms of colitis or severe gastrointestinal issues caused by Piqray?

A: Severe diarrhea can be a sign of colitis. Patients are specifically advised to watch for signs of severe diarrhea, stomach-area ( abdominal) pain, and the presence of mucus or blood in the stool, as these could indicate a serious gastrointestinal issue.

Piqray (alpelisib) tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (mathbf68 F to mathbf77 F), with temporary excursions permitted up to 30 C (86 F). The regulatory requirements strictly mandate that the medicine be stored in the original bottle and kept tightly closed to ensure protection from moisture. The desiccant pouch included in the container must not be removed. To prevent accidental exposure, the medicine must be kept out of the reach and sight of children. For disposal, any unused or expired Piqray must be handled in accordance with local requirements, which typically involves utilizing an approved drug take-back program. It should not be flushed down a toilet or drain.